Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd (NQ: ZLAB )

164.48 USD +7.01 (+4.45%)
Official Closing Price Updated: 5:42 PM EDT, Apr 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Zai Lab Ltd

< Previous 1 2 3 4 5 Next >
Thinking about trading options or stock in Apple, UnitedHealth Group, Zai Lab, PepsiCo, or Pfizer?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, UNH, ZLAB, PEP, and PFE. 
From PR Newswire
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
From GlobeNewswire News Releases
Zai Lab Announces Proposed Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Thinking about trading options or stock in Zai Lab, Novavax, Johnson & Johnson, Marathon Digital, or Riot Blockchain?
InvestorsObserver issues critical PriceWatch Alerts for ZLAB, NVAX, JNJ, MARA, and RIOT. 
From PR Newswire
Qiming's Duane Kuang, Nisa Leung Named on 2021 Forbes Midas List
Forbes today released the 2021 Midas List, a ranking of the world's top 100 venture capitalists. Duane Kuang and Nisa Leung, Managing Partners of Qiming Venture Partners, ranked on the list. 
From PR Newswire
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
From GlobeNewswire News Releases
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
From GlobeNewswire News Releases
Qiming's Portfolio Company Zhihu Lists on New York Stock Exchange
Qiming Venture Partners' portfolio company Zhihu (NYSE: ZH) on March 26th EST listed on the New York Stock Exchange. The issue price is US$9.5/ADS. The stock closed at US$8.5/ADS on the first trading... 
From PR Newswire
Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq
Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS. The stock opened at US$19.55/ADS and closed at... 
From PR Newswire
Zai Lab Announces Financial Results for Second-half and Full-year 2020
From GlobeNewswire News Releases
Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET 
From GlobeNewswire News Releases
First Cancer Early Screening Company Listed on HKEX as New Horizon Health Debuts
Qiming's portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company. 
From PR Newswire
Zai Lab Announces Upcoming Presentations in February Investor Conferences
From GlobeNewswire News Releases
Qiming Venture Partners Closes RMB Fund VI at RMB 2.852 billion
Qiming Venture Partners ("Qiming") today announced the final close of our RMB Fund VI at RMB 2.852 billion. 
From PR Newswire
Turning Point and Zai Lab Broaden Collaboration
From GlobeNewswire News Releases
Turning Point and Zai Lab Broaden Collaboration
From GlobeNewswire News Releases
Qiming Venture Partners' Portfolio Company APT Medical Listed on STAR Board of Shanghai Stock Exchange
Qiming Venture Partners' portfolio company APT Medical (SHSE: 688617) today successfully listed on the Science and Technology Innovation Board (the STAR Board) of Shanghai Stock Exchange. The issue... 
From PR Newswire
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
From GlobeNewswire News Releases
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
From GlobeNewswire News Releases
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
From GlobeNewswire News Releases
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
From GlobeNewswire News Releases
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
From GlobeNewswire News Releases
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
From GlobeNewswire News Releases
Qiming's Portfolio Company Antengene Lists on Main Board of HKEX
Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The issue price is HK$18.08 per share; the stock opens at HK$... 
From PR Newswire
Qiming Venture Partners Announces Final Closing of US$ 1.2 Billion Fund VII
Fund targets early stage healthcare and technology investments 
From PR Newswire
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-
From GlobeNewswire News Releases
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million
Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a $21 million Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital, SCVC and... 
From PR Newswire
Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer
From GlobeNewswire News Releases
Zai Lab Announces Upcoming Presentations in November Investor Conferences
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.